Prior Movesmirror the world’s best investors

🪞 Larry Robbins · Glenview

Long-short healthcare.

Style
Specialist
Disclosed holdings
44
Top pick hit rate
1.7%
Backtest edge
-2.2 pts/q

Hit rate is measured, not predicted: across 2,030 investor-quarters of walk-forward holdout, the name this model ranked first was the investor’s actual next new buy 1.7% of the time, against 0.62% for a name drawn at random from the same board. That is 2.77x chance. The model ranks the whole board; AUC and the rest of the scoring detail are on the how it works page.

Build a basket from the top picks →

🔮 Predicted next buys: quarter ending 2026-09-30

The model orders Larry Robbins · Glenview’s candidates for the next 13F filing. No public confirmation yet. The rate beside each name is the model’s own score rewritten as a measured quantity: how often a name in that position turned out to be the next buy across 2,030 investor-quarters of holdout. Picking at random from this board lands 0.62%.

#TickerCompanyMeasured hit ratevs base
1COOCooper Cos Inc/The1.7%2.8x
2DHIDr Horton Inc1.7%2.8x
3RRCRange Resources Corp1.7%2.7x
4MCHPMicrochip Technology Inc1.7%2.7x
5ABTAbbott Laboratories1.6%2.6x
6DTDynatrace Inc1.6%2.6x
7ICEIntercontinental Exchange In1.6%2.5x
8BRKRBruker Corp1.6%2.5x
9DVNDevon Energy Corp1.5%2.5x
10NOWServicenow Inc1.5%2.4x

📉 Predicted exits, conviction fading

Of Larry Robbins · Glenview’s current disclosed holdings, the names a model flags as most likely to be EXITED or TRIMMED next quarter, before the 13F shows it. Model score (not a calibrated probability), ranked. Holdings as of 2026-06-30.

TickerCompanyWeightLast moveSell likelihood
AMDAdvanced Micro Devices Inc3.16%trimmed last Q▲▲ 67
BRKRBruker Corp0.28%just entered▲▲ 67
DOCNDigitalocean Hldgs Inc0.24%trimmed last Q▲▲ 64
ONTOOnto Innovation Inc1.42%trimmed last Q▲▲ 62
CAHCardinal Health Inc0.08%just entered▲▲ 61
PRMBPrimo Brands Corporation0.18%trimmed last Q▲▲ 61
TECHBio-Techne Corp0.08%trimmed last Q▲▲ 61
AMATApplied Matls Inc0.86%trimmed last Q▲▲ 61

⚠️ This predicts the ACTION (whether Larry Robbins · Glenview reduces the position), not a return and not a short. A 13F shows long positions only, so a “sell” here means exiting or cutting a long, never shorting the stock. Walk-forward validated on the decision (AUC ≈ 0.66), but acting on it is not shown to make money. Research, not advice.

📜 Top disclosed holdings: Jun 2026

TickerCompanyWeightLast change
GPNGlobal Pmts Inc11.77%➕ Added
CVSCvs Health Corp9.09%➖ Trimmed
THCTenet Healthcare Corp7.62%➕ Added
TMOThermo Fisher Scientific Inc5.73%➕ Added
AMZNAmazon Com Inc5.52%➕ Added
AG8Agilent Technologies Inc5.05%🆕 New
IWMIshares Tr5.02%➕ Added
DHRDanaher Corp Del3.97%➕ Added
METAMeta Platforms Inc3.66%➕ Added
SPYState Str Spdr S&P 500 Etf T3.54%🆕 New
AMDAdvanced Micro Devices Inc3.16%➖ Trimmed
TEVATeva Pharmaceutical Inds Ltd3.13%➖ Trimmed
VTRSViatris Inc2.86%✊ Held
UBERUber Technologies Inc2.36%➕ Added
CNCCentene Corp Del2.20%➖ Trimmed

Source: SEC Form 13F (public domain), long U.S. equity positions only, disclosed up to 45 days after quarter-end. Top 15 of 44 shown.

💲 Where they bought: accumulation cost

13F shows holdings, not trade prices. Implied average cost is total value ÷ shares; the zone is the price range that quarter, where they accumulated. “vs cost” is today versus that average. This is where they bought, not a future price.

TickerAvg costAccumulation zoneTodayvs cost
GPN$72.56$62–$75$92.74+27.8%
CVS$103.45$71–$104$93.91-9.2%
THC$187.08$161–$202$274.19+46.6%
TMO$501.36$438–$531$630.70+25.8%
AMZN$238.34$208–$275$259.77+9.0%
IWM$300.45$247–$300$293.93-2.2%
DHR$190.48$162–$198$215.36+13.1%
META$563.29$543–$688$571.10+1.4%
SPY$746.77$649–$758$771.10+3.3%
AMD$580.91$203–$581$470.72-19.0%

🎯 Disclosed options: calls vs puts

13F discloses option positions too. Calls lean bullish or levered; puts lean bearish or hedging. This is the not-just-buying side of what they disclose.

TickerPositionLean
IWMputsbearish / hedge
SPYputsbearish / hedge
AG8callsbullish / levered

Source: 13F option lines (put_call). Disclosed positions, not advice.

🧬 Factor fingerprint, the style behind the book

76% of Larry Robbins · Glenview’s day-to-day swings are explained by public, buyable factors (Fama-French 5 + momentum), regressed on their current disclosed book (14 of 15 names, ~421 trading days). Market beta 1.01.

growth
value
large-cap
small-cap
low-quality
quality
contrarian
momentum
aggressive
conservative

⚠️ This is the part the great investors can’t hide: their style is a tilt toward known factors, and every one of these is sold as a cheap index ETF. Buying the factors gets you most of the book for a few basis points. What’s left after the factors (the residual) is noisy on a single concentrated book and is not a reliable edge, read this as transparency about the style you’re copying, not a secret signal. Loadings are in-sample on current static weights, U.S. long positions only. Research, not advice.

📈 This mirror’s track: backtest vs S&P 500

Avg edge / quarter
-2.2 pts
Quarters beating S&P
11/34
Avg quarterly return
+1.2%
-12%98%208%2017-092021-122025-12This mirror (backtest)S&P 500

⚠️ Read this honestly. Leak-free walk-forward backtest: top-10 predicted new buys ranked from a broad ~2,000-name universe known at the rebalance date, equal-weight, 1-quarter holds, complete quarters only, gross (before costs). Small samples, per-investor edges are noisy and not statistically significant. The consensus mirror's backtest shows +2.2 pts/quarter net vs the S&P 500 over 35 complete quarters (2017Q3 to 2026Q1), directional, NOT statistically significant (t≈1.3; 95% CI includes zero). Most of that average is one quarter: 2026Q1 posted a +47.5 pt edge, roughly half of it two AI-hardware names (SNDK +258%, AMD +186%) marked at what proved to be a local peak; excluding it the edge is +0.9 pts/quarter. Past performance does not predict future results. Not investment advice.

🔔 Follow this mirror

New filings and predicted-buy refreshes are published to every reader at once, weekly digest (email) · build a basket.

Prior Moves is a research publication: one impersonal model portfolio per investor, identical for every reader. You place any trades yourself at your own broker. No execution, no custody, no individualised advice.